- Understand the key points of recent FDA guidance aimed at enhancing diversity and equity in clinical trials
- Discuss how recent FDA guidance supports patient optionality in clinical trials, especially for underrepresented populations
- Identify actionable strategies for integrating FDA guidance into clinical trial designs to achieve diversity and innovation goals
- Explore the potential impact of FDA guidance on future clinical trials, with an emphasis on patient-centricity and inclusivity
